Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

Latest News

Malaysia climber at hospital after 2 days alone on Annapurna

Apr 26, 2019

KATHMANDU, Nepal — A Malaysian mountain climber was being treated in a hospital in Nepal's capital Friday after being stranded nearly two days alone near the summit of Annapurna. A helicopter crew searching for the missing climber on Thursday spotted Wui Kin Chin waving his hands at them, and rescuers brought him down to a lower camp. At the time of his rescue, Chin had been without an oxygen bottle, food and water for over 40 hours, said Mingma Sherpa, the head of Seven Summit Treks, which arranged his expedition. Chin was flown to the capital, Kathmandu, on Friday and...

Despite big plans, N. Korea's trains still go almost nowhere

Apr 26, 2019

TOKYO — North Korean leader Kim Jong Un's decision to take a train to his summit with President Vladimir Putin in Russia's far east hints at the potential of a much bigger dream long held by many in Asia: unimpeded travel by rail from the southern tip of the Korean Peninsula to Moscow and beyond. The economic benefits range from linking big, thriving markets and bolstering regional cooperation to slashing costs and travel durations. But with sanctions and distrust standing in the way, it could be a very long time before any trains working their way north from Seoul will...

NRA diminished from role played in 2016 election

Apr 26, 2019

WASHINGTON — The nation's largest gun rights organization played a pivotal role in President Donald Trump's victory in 2016. Three years later, the National Rifle Association is limping toward the next election divided and diminished. It's a reversal that has stunned longtime observers and that is raising questions about the one-time kingmaker's potential firepower heading into 2020 as Trump and Vice President Mike Pence prepare to headline the group's annual convention in Indianapolis on Friday. "I've never seen the NRA this vulnerable" said John Feinblatt, president of Everytown for Gun Safety, a nonprofit that advocates for gun control measures. In...

Putin: Belt and Road fits with Eurasian Economic Union goals

Apr 26, 2019

BEIJING — China's Belt and Road infrastructure initiative meshes perfectly with the goals of the Russian-led Eurasian Economic Union, Russian President Vladimir Putin said Friday. Putin's comments to a Belt and Road forum in Beijing may help alleviate concerns over potential tensions between China and Russia, given Beijing's rapidly expanding economic footprint in Central Asia, Moscow's traditional sphere of influence. Putin told some three-dozen leaders attending the conference that China's moves "fit perfectly into our plans." The Eurasian Economic Union groups Russia with Armenia, Belarus, Kazakhstan and Kyrgyzstan in a common market that seeks to remove barriers to the free...

Deutsche Bank earnings up in 1st quarter but revenues drop

Apr 26, 2019

BERLIN — Deutsche Bank says it saw its profit improve by 67 percent in the first quarter, though revenue dropped 9 percent as proceeds from trading declined sharply. Germany's biggest bank reported details of its January-March earnings on Friday, a day after it abandoned talks on a possible merger with German peer Commerzbank. The company said net profit was 201 million euros ($224 million), compared with 120 million euros a year earlier. Revenues dropped to 6.35 billion euros from 6.98 billion euros. The bank said revenues from fixed income sales and trading were off 19 percent at 1.5 billion euros,...

Search

Deck Biz is an intelligent platform providing international and regional business news updates. You won’t get these insights elsewhere other than Deck Biz.

Contact us: sales@deckbiz.com